SINGAPORE – Several cancer-related organisations in Singapore are excited with the recent announcement that Medicare, the United States federal health insurance programme, will reimburse patients with advanced lung cancer who use a technology developed in Singapore.
Lucence, which has headquarters in Singapore and the US, said: “This approval establishes Lucence as the first and only Asian-headquartered healthcare services company to secure United States national insurance coverage.”
Already a subscriber? Log in
Read the full story and more at $9.90/month
Get exclusive reports and insights with more than 500 subscriber-only articles every month
ST One Digital
$9.90/month
No contract
ST app access on 1 mobile device
Unlock these benefits
All subscriber-only content on ST app and straitstimes.com
Easy access any time via ST app on 1 mobile device
E-paper with 2-week archive so you won't miss out on content that matters to you
